FirsthandHealth
medRxiv PreprintsInternational16 November 2026

Nirsevimab effectiveness against RSV hospitalizations in children 8-23 months at risk of severe RSV

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Importance: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in high-risk young children during their second RSV season. Nirsevimab, a long-acting monoclonal antibody against RSV, is recommended for some children who are at increased risk for severe RSV and entering their second RSV season to prevent severe RSV disease. Because of limited eligibility criteria for second season nirsevimab, estimating its effectiveness is challenging. Objective: We evaluated nirsevimab effectiveness against RSV-associated hospitalizations among young children eligible to receive nirsevimab
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.